Targeting Rare Genomic Alterations in Advanced Thyroid Cancer: What Endocrinologists Need to Know

Join us for a live CME/ABIM MOC–certified workshop series tailored to endocrinologists on managing advanced thyroid cancer with genomic alterations in NTRK, RET, and BRAF, including expert guidance on biomarker testing, review of the latest clinical data on targeted therapies, and discussion of patient cases. Register now!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

  • Introduction
  • Overview of Thyroid Cancer: Most Common Genetic Drivers
  • Biomarker Testing in Thyroid Cancer
  • Clinical Data and Current Indications of Therapies Targeting Common Genetic Drivers in Advanced Thyroid Cancer
  • Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Co-Chair
Maria E. Cabanillas, MD

Professor
Department of Endocrine Neoplasia and Hormonal Disorders
The University of Texas MD Anderson Cancer Center
Houston, Texas

Co-Chair
Lori J. Wirth, MD

Associate Professor
Medical Oncology
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Faculty
Sarimar Agosto Salgado, MD

Assistant Member, Endocrine Oncology
Oncologic Endocrinologist
Head and Neck-Endocrine Oncology
Moffitt Cancer Center
Tampa, Florida

Faculty
Marcia Brose, MD, PhD, FASCO

Professor
Department of Medical Oncology
Sidney Kimmel Medical College
Thomas Jefferson University
Director, Sidney Kimmel Cancer Center
Vice Chair, Medical Oncology
Sidney Kimmel Medical College
Jefferson Northeast
Philadelphia, Pennsylvania

Faculty
Francis P. Worden, MD

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with thyroid cancers.

Target Audience
This program is intended for endocrinologists and other healthcare professionals who care for patients with thyroid cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with thyroid cancer
  • Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive thyroid cancer and RET inhibition in RET-altered thyroid cancer
  • Manage treatment-related symptoms associated with the treatment of RET-altered or NTRK fusion–positive cancer
  • Refer eligible patients with NTRK fusion–positive and RET-altered thyroid cancer for ongoing clinical trials

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.